Beigene Ltd (ADRs) (BGNE)

Explore Beigene Ltd (ADRs) (BGNE) share price insights and trends to guide your investment strategy. Stay informed with FP Markets Ecuador.

Pricing is indicative. Past performance is not a reliable indicator of future results. Log in to see latest markets data.

Beigene Ltd (ADRs) (BGNE) Profile

Beigene Ltd (ADRs) (BGNE.xnas) is a biotechnology company headquartered in Beijing, China. Beigene specialises in the development of drugs for cancer treatment. Its products include tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton’s tyrosine kinase inhibitor, which became the 1st cancer drug developed in China to gain approval from the U.S Food and Drug Administration. Beigene has offices in China, Australia, the United States and Europe and employs approximately 3,500 people worldwide. Beigene Ltd stock is listed on the NASDAQ and had a market capitalisation of $26.59B (USD) as of January 2022 and $1.11B (USD) in 2021 yearly revenues. At the end of 2021, the company announced an option, collaboration and licence agreement with Novartis Pharma AG to develop, manufacture and commercialise Beigene’s investigational TIGIT inhibitor ociperlimab in Europe, North America, and Japan. Additionally, both companies entered into an agreement granting Beigene rights to market, promote and detail five approved Novartis oncology products across designated regions of China. The European Commission (EC) approved Beigene’s drug BRUKINSA to treat adult patients with Waldenstrom’s macroglobulinemia (WM).

Start Trading Beigene Ltd (ADRs) (BGNE) with a Market Leader Today

Beigene Ltd (ADRs) (BGNE) Trading FAQ

Shares represent units of ownership within a company. Shares are also known as stocks or equities. Dividend payments are common with some companies, a method of sharing company profits with shareholders. In addition to traditional share dealing, however, traders can access derivatives: trading instruments derived from the movement of an underlying share price.

Individual stock CFDs (contract for differences) fall under the umbrella of derivative products, an effective low-cost trading vehicle. While CFDs do not grant shareholder privileges, active CFD positions may receive a dividend if executed before the ex-dividend date.

Start Trading
in minutes

Get instant Updates in Telegram